jain.com

Dollar Warrants issuance to lenders

Company: TeraWulf

This claim was marked delayed on September 14, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
financing
Statement date
2023-03-02
Promised by
2024-04-01
Promised amount
13333333.0 shares
Current status
delayed

The claim, verbatim

Company issued 13,333,333 Dollar Warrants to lenders representing 5% of fully diluted equity with exercise price of $1.00 per share, exercisable from April 1, 2024 through December 31, 2026

Source (primary)

TeraWulf 8-K filed 2023-03-03 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗

Quote: “13,333,333 warrants to purchase an aggregate number of shares of the Company's common stock equal to 5.0% of the fully diluted equity of the Company as of the Fifth Amendment Effective Date with an exercise price of $1.00 per share”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms TeraWulf 8-K filed 2023-03-03

Quote: “13,333,333 warrants to purchase an aggregate number of shares of the Company's common stock equal to 5.0% of the fully diluted equity of the Company as of the Fifth Amendment Effective Date with an exercise price of $1.00 per share”

View cached copy (2026-09-13)Live source ↗

Record of changes

September 13, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 14, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.